MedTrace Logo

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

NCT06746519 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2024-12-24

No results posted yet for this study

Summary

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.

Conditions

Interventions

DRUG

BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine

The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.

Sponsors & Collaborators

  • BioNova Pharmaceuticals (Shanghai) LTD.

    collaborator INDUSTRY

  • Chen Suning

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-25
Primary Completion
2025-12-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06746519 on ClinicalTrials.gov